09 Aug MEDIA RELEASE: 4DMedical signs commercial contract with pharmaceutical company
MEDIA RELEASE 9 August 2021
4DMedical signs commercial contract with pharmaceutical company
Respiratory imaging disruptor 4DMedical (ASX:4DX) today announced the signing of a commercial contract with Novartis.
Under the terms of the agreement, XV Ventilation Reports will be provided to Novartis on a commercial basis. These highly visual, multi-dimensional reports will be used to provide performance comparisons to existing imaging modalities used for this purpose through a program of medical imaging to be conducted at the University of Miami.
This agreement aims to further validate the capabilities of the company’s XV Technology with particular application to early-stage research in the pharmaceutical industry.
“The pharmaceutical industry seeks to discover, develop and deliver breakthrough treatments to patients as rapidly as possible,” said 4DMedical’s Vice President of Medical and Clinical Affairs, Dr Jason Kirkness, who is coordinating key aspects of the trial with the University of Miami. “Application of our XV Technology enables this at a time when speed from laboratory to patient has never been more valued.”
“4DMedical’s XV LVAS imaging capability is the ideal complementary technology for the global pharmaceutical industry,” said Dr Andreas Fouras, Managing Director and Chief Executive Officer of 4DMedical. “We are working to optimise protocols that enable our technology to support faster and more cost-efficient drug design and development.”